US EditionPublished • loading... • Updated
Tenpoint Therapeutics Ltd. Announces FDA Acceptance of New Drug Application for BRIMOCHOL™ PF for the Treatment of Presbyopia
Summary by Business Wire
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
FDA Accepts Tenpoint's New Drug Application for Brimochol PF for the Treatment of Presbyopia
Tenpoint Therapeutics announced that the FDA has accepted the new drug application (NDA) for Brimochol PF for the treatment of presbyopia. The FDA has set a Prescription Drug User Fee Act (PDUFA) date of January 28, 2026. The FDA noted that it is not planning to hold an advisory committee meeting to discuss this application. “This milestone marks a significant step forward in our transition toward becoming a commercial-stage company, and we look…
Coverage Details
Total News Sources4
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
